Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced  that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the 17^th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019, at 11:10 a.m. ET in New York City. 

A live audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.

Contacts:

Lori Melançon

Vice President, Corporate Communications and Investor Relations

+1 (617) 949-5296

lori.melancon@rubiustx.com

Media Contact: 

Dan Budwick

1AB

+1 (973) 271-6085

dan@1abmedia.com